HALB (Halberd) Total Equity: $-0.93 Mil (As of Jul. 2023)


What is Halberd Total Equity?

Halberd HALB -1.05% Total Equity is $-0.93 Mil as of Jul. 2023.

Halberd's total equity for the quarter that ended in Jul. 2023 was $-0.93 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Halberd Total Equity Historical Data

* Premium members only.

The historical data trend for Halberd's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Total Equity Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Total Equity
-0.04 -0.73 -0.93

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Total Equity -0.04 -0.73 -0.93

Halberd Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Halberd's Total Equity for the fiscal year that ended in Jul. 2023 is calculated as

Total Equity=Total Assets(Q: Jul. 2023 )-Total Liabilities(Q: Jul. 2023 )
=0.012-0.939
=-0.93

Halberd's Total Equity for the quarter that ended in Jul. 2023 is calculated as

Total Equity=Total Assets(Q: Jul. 2023 )-Total Liabilities(Q: Jul. 2023 )
=0.012-0.939
=-0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-0.93 Mil mean?
Halberd (HALB) has a Total Equity of $-0.93 Mil as of Jul. 2023. The total amount of equity as record on a company's balance sheet. View historical data for Halberd and its competitors.
Is Halberd's Total Equity too high?
Halberd's current Total Equity is $-0.93 Mil.
How does Halberd's Total Equity compare to GRI and OCEA?
Halberd's Total Equity of $-0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Halberd and its competitors. Halberd's current Total Equity is $-0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Total Equity of $-0.93 Mil. The current Total Equity is $-0.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Halberd (HALB), the current Total Equity is $-0.93 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.